| Literature DB >> 34771035 |
Edwin R Sukandar1, Sutin Kaennakam2, Pia Raab3, Xuehong Nöst3, Kitiya Rassamee4, Rudolf Bauer3, Pongpun Siripong4, Taslim Ersam5, Santi Tip-Pyang1, Warinthorn Chavasiri1.
Abstract
Garcinia picrorhiza, a woody plant native to Sulawesi and Maluku Islands, Indonesia, has been traditionally used as a wound healing ointment. In our continuous search for bioactive compounds from this plant, 15 phenolic compounds were isolated from its stem bark, including a previously undescribed dihydroisocoumarin, 2'-hydroxyannulatomarin, and two undescribed furanoxanthones, gerontoxanthone C hydrate and 3'-hydroxycalothorexanthone. The structures of the new metabolites were elucidated on the basis of spectroscopic analysis, including 1D and 2D NMR and HRESIMS. Gerontoxanthone C hydrate possessed cytotoxicity against four cancer cells (KB, HeLa S3, MCF-7, and Hep G2) with IC50 values ranging from 5.6 to 7.5 µM. Investigation on the anti-inflammatory activities showed that 3'-hydroxycalothorexanthone inhibited NO production in RAW 264.7 and BV-2 cell lines with IC50 values of 16.4 and 13.8 µM, respectively, whereas only (-)-annulatomarin possessed inhibition activity on COX-2 enzyme over 10% at 20 µM. This work describes the presence of 3,4-dihydroisocoumarin structures with a phenyl ring substituent at C-3, which are reported the first time in genus Garcinia. These findings also suggest the potential of furanxanthone derivatives as cytotoxic and anti-inflammatory agents for further pharmacological studies.Entities:
Keywords: Clusiaceae; Garcinia picrorhiza; anti-inflammatory; cytotoxic; isocoumarin; xanthone
Mesh:
Substances:
Year: 2021 PMID: 34771035 PMCID: PMC8587515 DOI: 10.3390/molecules26216626
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Isolated compounds (1‒15) from the stem bark of Garcinia picrorhiza.
1H- (400 MHz) and 13C- (100 MHz) NMR spectroscopic data of compounds 3‒5 recorded in acetone-d6 (δ in ppm).
| Position | 3 | Position | 4 | 5 | |||
|---|---|---|---|---|---|---|---|
|
|
|
| |||||
| 1 | 171.3 | 1 | 157.5 | 159.5 | |||
| O-2 | 2 | 116.9 | 117.9 | ||||
| 3 | 5.93, dd (11.6, 4.0) | 77.0 | 3 | 164.5 | 168.2 | ||
| 4a | 3.13, dd (16.4, 4.0) | 34.1 | 4 | 104.6 | 6.38, s | 90.4 | |
| 4b | 3.18, dd (16.4, 11.6) | 4a | 155.8 | 159.5 | |||
| 5 | 6.42, s | 107.3 | 10a | 146.9 | 149.8 | ||
| 6 | 157.7 | 5 | 133.4 | 6.90, d (8.8) | 107.0 | ||
| 7 | 134.8 | 6 | 151.9 | 7.33, d (8.8) | 124.6 | ||
| 8 | 157.7 | 7 | 6.96, d (8.4) | 113.9 | 141.4 | ||
| 9 | 102.7 | 8 | 7.61, d (8.4) | 117.3 | 148.0 | ||
| 10 | 137.4 | 8a | 114.7 | 108.3 | |||
| 1′ | 126.2 | 9 | 182.0 | 185.5 | |||
| 2′ | 155.0 | 9a | 104.4 | 103.4 | |||
| 3′ | 6.95, d (8.0) | 116.4 | 1′ | 44.6 | 43.6 | ||
| 4′ | 7.21, t (8.0) | 130.4 | 2′ | 4.53, q (6.4) | 91.5 | 4.51, t (5.6) | 96.0 |
| 5′ | 6.94, t (8.0) | 120.8 | 3′ | 1.41, d (6.4) | 14.8 | 3.91, d (5.6) | 61.4 |
| 6′ | 7.49, d (8.0) | 127.8 | 4′ | 1.24, s | 21.1 | 1.38, s | 20.6 |
| OH-8 | 11.44, brs | 5′ | 1.49, s | 25.7 | 1.57, s | 26.8 | |
| OCH3-7 | 3.84, s | 60.8 | 1″ | 2.91, m | 18.3 | ||
| 2″ | 1.81, m | 42.9 | |||||
| 3″ | 71.8 | ||||||
| 4″ | 1.32, s | 29.7 | |||||
| 5″ | 1.32, s | 29.7 | |||||
| OH-1 | 13.26, s | ||||||
Figure 2Key COSY (blue line) and HMBC (red arrow) correlation of compounds 3‒5.
Cytotoxic activity of the isolated compounds against five human cancer cell lines.
| Compound | IC50 ± SEM (µM) a | ||||
|---|---|---|---|---|---|
| KB | HeLa S3 | MCF-7 | Hep G2 | HT-29 | |
|
| 7.5 ± 0.8 | 5.6 ± 0.1 | 5.7 ± 0.3 | 6.3 ± 0.6 | 20.3 ± 0.6 |
|
| 12.1 ± 0.1 | 20.7 ± 0.6 | 15.6 ± 0.3 | 22.8 ± 0.4 | inactive |
|
| 5.1 ± 0.4 | 6.0 ± 0.5 | 6.5 ± 0.2 | 10.0 ± 0.2 | inactive |
|
| 0.2 ± 0.1 | 0.3 ± 0.1 | 4.9 ± 0.4 | 3.8 ± 0.5 | 21.9 ± 1.2 |
|
| 11.4 ± 1.7 | 15.2 ± 1.3 | NT | NT | NT |
| Doxorubicin c | 0.02 ± 0.01 | 0.15 ± 0.02 | 1.29 ± 0.02 | 1.00 ± 0.17 | 0.59 ± 0.03 |
a Results are expressed as the means ± SEM of three replicates. b The cytotoxic results based on our previous work [11,39]. c Doxorubicin was used as the positive control. Note: NT= not tested, IC50 ≤ 10 µM = good cytotoxicity, 10 µM < IC50 ≤ 30 µM = weak cytotoxicity. The other compounds were inactive (IC50 > 30 µM).
Figure 3(a) NO production inhibitory effects and (b) cytotoxic properties of compounds 1‒8 at a final concentration of 50 µM in LPS-IFN-γ-induced RAW 264.7 macrophages and BV-2 microglial cells. L-NMMA was used as the positive control at 100 µM. The NO inhibition of control group (LPS-IFN-γ-induced cells with 1% DMSO) was set as 100% (n = 6).
IC50 values (µM) d of compounds 4, 5, and 7 on inhibition of NO production in LPS-IFN-γ-induced RAW 264.7 macrophages and BV-2 microglial cells.
| Compound | RAW 264.7 | BV-2 | ||
|---|---|---|---|---|
| iNOS | Cytotoxicity | iNOS | Cytotoxicity | |
|
| 84.3 ± 3.5 | >200 | 20.0 ± 4.0 | 27.7 ± 6.4 |
|
| 16.4 ± 4.5 | >200 | 13.8 ± 1.6 | 74.7 ± 2.1 |
|
| 45.6 ± 6.5 | 85.6 ± 6.9 | 28.7 ± 2.3 | 31.7 ± 4.7 |
d Results are expressed as the means ± SEM (n = 6) of two independent experiments. L-NMMA at 100 µM was used as the positive control with inhibition of 64.1 ± 4.1% in RAW 264.7 and 44.1 ± 5.2% in BV-2 cell lines.
Inhibitory activity e of the isolated compounds against COX enzymes.
| Compound | % Inhibition at 20 µM | |
|---|---|---|
| COX-1 | COX-2 | |
|
| <10 | 10.4 ± 5.0 |
|
| 24.2 ± 12.3 | <10 |
|
| 32.4 ± 7.9 | <10 |
|
| 31.2 ± 21.7 | <10 |
|
| 15.4 ± 7.5 | <10 |
|
| 24.0 ± 15.0 | <10 |
|
| 22.6 ± 2.2 | <10 |
|
| 18.3 ± 12.1 | <10 |
| Indometacin f | 78.4 ± 4.1 | NT |
| Celecoxib g | NT | 83.5 ± 4.8 |
e Results are expressed as the means ± SD (n = 4) of two independent experiments. f Indometacin was used as the positive control for COX-1 at 1.25 µM. g Celecoxib was used as the positive control for COX-2 at 8.8 µM. The other compounds showed no activity against COXs with inhibition lower than 10%. NT = not tested.